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COPD Instrument (EMSCI) was designed to measure the occurrence and severity 
of early morning symptoms in patients with COPD and the impact of those symp-
toms on activity limitation and rescue medication use. This abstract describes 
the psychometric analysis conducted to examine the EMSCI’s reliability and 
validity. Methods: Psychometric properties were examined using data from a 
phase 3 clinical trial. Item analyses were conducted using data from the baseline 
week (weekly average) as well as the morning of Day 1 (both time points prior to 
first dose) from a random split half sample, stratified by baseline GOLD status. 
Descriptive statistics, factor analysis, and Rasch model analysis were conducted 
to examine item performance and final items were selected. Test-retest reli-
ability was assessed for the final instrument using intra-class coefficient (ICC). 
Correlations with baseline assessments including the St. George Respiratory 
Questionnaire (SGRQ), Exacerbations of Chronic Obstructive Pulmonary Disease 
Tool - Respiratory Symptoms (EXACT-RS), and forced expiratory volume in 1 
second (FEV1) were used to evaluate concurrent validity. Results: Patients in 
the sample (N= 1663) were aged 40-93 years (mean 63.93 ± 8.89) and 53% male. 
About 31% of patients experienced early morning symptoms that were at least 
moderate in severity on Day 1. A one-factor structure was confirmed with factor 
analysis for symptom severity items. Test-retest reliability was confirmed with 
symptom severity (ICC= 0.84), activity limitation (ICC= 0.85) and rescue medication 
(ICC= 0.62). Concurrent validity was supported by the EMSCI’s significant posi-
tive correlation with both the SGRQ and EXACT-RS. ConClusions: Results sug-
gest that the EMSCI is a reliable and valid instrument to evaluate early morning 
symptoms in COPD and can potentially be used to collect data to support clinical 
study endpoints.
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objeCtives: To evaluate the impact of the HEPAiRx® technology on the qual-
ity of life (QoL) and asthma related outcomes for a pediatric asthma popula-
tion. Methods: The HEPAiRx® is a window mounted patented room-air purifier 
with HEPA filtration for particulate removal and fresh outside air exchange for VOC 
removal that effectively reduces indoor air pollutants that have been associated 
with asthma. It also has built-in heating and air conditioning so the room can be 
isolated from surrounding spaces and contaminants. The intended sample size 
for this study was 25; however three subjects were enrolled due to recruitment dif-
ficulties. The 16-week prospective portion of the study consisted of 4 home visits. 
Health care resources, a daily diary, pulmonary function tests (PFTs), Forced Vital 
Capacity (FVC), Forced Expiratory Volume (FEV1) and QoL outcomes were captured. 
Health care resources were captured retrospectively for the same calendar period 
in the previous year. The validated Pediatric Asthma Quality of Life Questionnaire 
(PAQLQ) and Pediatric Asthma Caregiver Quality of Life Questionnaire (PACQLQ) 
were administered. Results: The PFTs indicated improvement over the prospec-
tive period. FVC mean value improved by 18.6% from baseline to week 16; FEV1 
mean value improved by 22.0%. The PAQLQ instrument indicated an improvement 
in the subjects’ asthma related QoL; the symptom domain score increased by 46.8% 
from baseline to week 16. The overall score increased by 15.5%. PACQLQ assessed 
mean overall score improved by 4.3% for the study period. Health care resources 
were compared for the study period and the corresponding period in the previous 
year. The resources associated with office visits and medications increased from 
retrospective to prospective. No ED visits were captured and laboratory tests were 
minimal. ConClusions: The HEPAiRx® intervention demonstrated significant 
improvements in the HRQoL and PFT domains. The health care resources increased 
from the retrospective to prospective. Additional research is warranted.
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objeCtives: Chronic obstructive pulmonary disease (COPD) is a leading cause 
of death and disability in the US. Due to its progressive nature and high preva-
lence, COPD imposes a considerable burden on Medicare and will be important 
to reimbursement under the Affordable Care Act. Evidence suggests that oral 
nutritional supplements (ONS) may be an effective means of improving COPD 
outcomes, but the extent of this effect among aged 65+ Medicare inpatients 
is unclear. Methods: Analyses were conducted using the Premier Research 
Database on Medicare patients aged 65+ and carrying a primary diagnosis of 
COPD. Propensity score matching was employed to create a one-to-one matched 
sample of ONS and non-ONS episodes. Because ONS were likely to be given to 
patients with poor unobserved health status, instrumental variables (IV) regres-
sion analysis was performed to address selection bias. IV analyses quantified 
the effect of ONS use on length of stay (LOS), episode cost, and the probability 
of 30-day readmission. Covariates included patient and provider characteristics 
and a time trend. Results: Out of 10,322 ONS episodes and 368,097 non-ONS 
episodes, a one-to-one matched sample was created (N= 14,326). IV regression 
analysis indicated that ONS use reduced LOS by 1.88 days (21.5%), from 8.75 to 6.87 
days (p< 0.01). Similarly, episode costs were reduced by $1,570 (12.5%), from $12,523 
to $10,953 (p< 0.01). Among those episodes which could be tracked for follow-up, 
ONS use lowered the probability of 30-day readmission by 13.1%, from 0.335 to 
0.291 (p< 0.01). ConClusions: ONS presents an inexpensive, effective means for 
through item completion, internal validity was evaluated using factorial structure 
and internal consistency. Results: Face validity suggested that the H-CSRI had 
satisfactory psychometric proprieties (missing data up to 20%). There were floor 
effects for 6 items and no item with ceiling effect. Factor analysis explained 84% 
of the total variance and demonstrated acceptable construct validity for the motor 
subscale. The H-CSRI showed an acceptable reliability (Cronbach’s alpha coefficients 
were higher than 0.80). The items internal consistency scores were higher than 0.40 
and the correlations between items and their respective rest-scores in one dimen-
sion were all higher than the correlations with another dimension. ConClusions: 
These data support the validity of the motor and functional scales of the H-CSRI to 
assess the health status for patients with HD in US. A limitation of this study is that 
the behavioural subscale was not assessed because items related to patients were 
not linked with those related to caregivers. Further analyses should be conducted 
to assess the validity of the behavioural subscale.
PRS56
the diSeASe BuRden ASSociAted With infAnt hoSPitAlizAtion foR A 
loWeR ReSPiRAtoRy tRAct infection (lRti) in cAnAdA
Vo P.1, Mitchell I.2, Gooch K.L.1, Manthena S.1, Holton M.J.3, Ruff M.2
1AbbVie, North Chicago, IL, USA, 2University of Calgary, Calgary, AB, Canada, 3Lorimer 
Enterprises Inc., Red Deer, AB, Canada
objeCtives: Infant hospitalizations for lower respiratory tract infections (LRTIs) 
are common in children under one year of age, of which respiratory syncytial 
virus (RSV) is the major cause. The economic impact of infant hospitalizations for 
respiratory infections has proven to be substantial; however the socioeconomic 
burden it has on parents and caregivers is not as well understood. Methods: 
The Parent Burden Study was a multinational prospective study designed to 
determine the humanistic and economic burden of infant LRTI hospitalizations. 
Canadian data was collected over two consecutive RSV seasons (2010/2011 and 
2011/2012). Direct health care resource utilization data (e.g. length of hospitali-
zation stay (LOS) and intensive care unit (ICU) admission) were obtained from 
medical chart reviews. Lost work productivity was assessed by surveys adminis-
tered to parents at the time of infant discharge using the Work Productivity and 
Activity Impairment questionnaire specific to caregivers of infants hospitalized 
with respiratory illness. Results: 67 infants (54 term, 13 preterm), < 1 year of 
age were included. 100% of infants had a confirmed RSV diagnosis. The mean 
LOS was 5.68 days (5.65 days term, 5.81 days preterm). 13.4% of infants (13% term 
and 15.4% preterm) required ICU admission and 95.5% had supplemental oxygen 
(96.3% term, 92.3% preterm). Among fathers who completed the survey 37 (84%) 
reported they were currently employed. Absenteeism was 51.27%, presenteeism 
(impaired productivity while at work) was 62.70%, and overall work impairment 
was 78.35%. Of mothers who completed the survey 9% reported they were cur-
rently employed. Of working mothers, absenteeism was 27.78%, presenteeism was 
21.43% and overall work impairment was 72.92%. On average, fathers reported 
74.19% daily activity impairment and mothers reported 88.04% due to their child’s 
hospitalization. ConClusions: This study shows that infant hospitalizations 
due to severe RSV result in an economic burden borne by the health care system, 
employers and parents in Canada.
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objeCtives: Asthma is the most common chronic disease in children. To date, there 
is no asthma symptom diary suitable for use in pediatric clinical trials of asthma 
therapy to support labeling claims in children. This study was to characterize the 
symptom experiences in children with asthma and their parents/caregivers (par-
ents), to elicit concepts and language surrounding children’s asthma experiences 
directly from children (ages 4-11 years) and parents, to understand the age at which 
children can comprehend and report asthma symptoms. Methods: Concept elici-
tation interviews were conducted, consistent with the FDA Guidance for Industry 
on Patient-Reported Outcomes. Child and parental perceptions of the asthma 
symptom experiences were elicited from child-parent dyads. Data from interviews 
were analyzed, using a content analysis approach with ATLAS.ti qualitative data 
analysis software. Results: A total of 27 child-parent dyads from sites in the US 
were interviewed. Children and parents were generally consistent in their report-
ing of daytime asthma symptoms; including coughing, wheezing, chest tightness/
discomfort, and shortness of breath. Both children and parents reported that these 
symptoms may also occur at night and lead to nighttime awakenings. Children 
were more aware of chest tightness and discomfort; parents were more aware of 
wheezing, which may be easier to detect by an observer. Younger children were less 
able to accurately describe their symptoms over longer timeframes/recall periods 
than older children. Children and their parents described symptom severity in terms 
of intensity and frequency. Results supported a daily recall of symptoms as most 
appropriate. ConClusions: The qualitative data support the development of an 
observer asthma symptom diary for parents of children 4 years and older with a 
daily recall period. In addition, children 8 years of age and older may also be able to 
accurately report their symptoms on a daily basis.
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objeCtives: Early morning symptoms impact the quality of life of patients with 
chronic obstructive pulmonary disease (COPD). The Early Morning Symptoms of 
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in order to enhance and promote smoking cessation efforts in this population. 
Finally, the impact of inclusion of these products on the monthly prescription cap 
was also evaluated. Methods: Mississippi Medicaid FFS prescription claims data 
for the years 2012-2013 were analyzed. Only beneficiaries enrolled continuously 
in Medicaid were considered in the analysis. Dual eligibles were excluded from 
the study. Drugs dispensed were identified using National Drug Codes. Utilization 
as well as medication use patterns of nicotine replacement therapies, bupropion 
hydrochloride, and varenicline was studied. All results were reported by age, gen-
der, race, pregnancy status, and Medicaid plan ID. Distribution of beneficiaries 
in terms of number of fills for each drug was determined in order to assess new 
therapy starts and duration of therapy. Results: 366 (86.3%) of the beneficiaries 
on smoking cessation agents were prescribed bupropion while 33 (7.8%) used 
varenicline and only 18 (5.3%) used nicotine products. No other distinct patterns 
in therapy could be identified. 59 varenicline therapies were initiated but only 
13 of them continued until the third fill. In terms of the distribution of vareni-
cline therapies per beneficiary, 32 beneficiaries had only one therapy initiation 
while three beneficiaries had two therapy initiations including two starter packs 
and possibly following with continuation packs. On average, in any given month, 
65% of the eligible beneficiaries would benefit if these drugs were not included 
under the monthly prescription cap. ConClusions: A better understanding of 
utilization and treatment patterns can assist practitioners in making appropriate 
treatment decisions to help promote smoking cessation efforts in this population. 
Benefit designs such as removing copayments and/or allowing for smoking cessa-
tion therapies not to count against a prescription benefit limit will influence the 
increased utilization of these drugs.
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objeCtives: To identify and compare predictors of a successful cessation out-
come among adult smokers newly prescribed each type of smoking cessation 
medication. Methods: A retrospective cohort study was conducted using General 
Electric (GE) health care clinical data. Andersen’s Health Service Utilization model 
was used as conceptual framework. The outcome variable was being abstinent or 
not. The independent variables were categorized into predisposing, enabling, and 
need characteristics, including age, gender, race, region, payment type, specialty 
group, comorbidity, obesity, number of cigarettes smoked per day, smoking coun-
seling, and alcohol consumption. Three multivariate logistic regression models 
were conducted to identify predictors of successful outcome among adult smokers 
prescribed each type of smoking cessation medication. Results: In total, we iden-
tified 132,885 adult smokers who were newly prescribed varenicline, 4,045 adult 
smokers newly prescribed bupropion and 38,001 adult smokers newly prescribed 
nicotine replacement therapy (NRT) between 2006 and 2011. Among smokers who 
were newly prescribed varenicline, male smokers were less likely to be abstinent 
compared with female smokers (OR: 0.878, 95% CI: 0.851-0.907). Among smok-
ers being newly prescribed bupropion, smokers with depression (OR: 1.551, 95% 
CI: 1.111-2.164) were more likely to quit compared to those without depression. 
Among smokers being newly prescribed NRT, male smokers were more likely to be 
abstinent compared with female smokers (OR: 1.072, 95% CI: 1.011-1.136). Smokers 
with COPD (OR: 1.249, 95% CI: 1.121-1.392) were more likely to quit compared to 
those without COPD. ConClusions: Each different type of cessation medication 
may be particularly beneficial to certain sub-populations in real world. NRT may 
be more effective among patients with COPD compared to those without COPD. 
Bupropion may be more beneficial to smokers with depression compared to those 
without depression. NRT may be more beneficial to male smokers compared to 
female smokes. Varenicline may be more beneficial to female smokers compared 
to male smokers.
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objeCtives: To evaluate the prescribing rate of each type of smoking cessation 
medication among adult smokers in 2011. Methods: A retrospective cross-sec-
tional study was conducted using General Electric (GE) health care clinical data. 
Descriptive statistics were used to provide estimates of the prescribing rates of 
each smoking cessation medication (varenicline, bupropion, and nicotine replace-
ment therapy (NRT)) in 2011. All statistical analyses were performed using SAS 
version 9.3 (SAS Institute, Cary, NC) statistical package at a priori significance 
level of 0.05. Results: Total sample consisted of 886,604 current adult smokers 
in 2011. Among these smokers, 50,157 (5.66%) were prescribed a smoking cessation 
medication, of which, varenicline was the most commonly prescribed (n= 32,688, 
3.69%), followed by NRT (n= 17,716, 2.00%) and bupropion (n= 1,630, 0.18%). For 
those who were prescribed varenicline, 34.41% were aged between 18 and 40, 
58.03% aged between 41 and 64, and 7.56% aged more than 65. They were mostly 
comprised of white (47.84%), followed by races (47.62%) including Hispanic and 
Asian, and black (4.54%). For the smokers who were prescribed bupropion, 34.60% 
of them were aged between 18 and 40, 56.13% aged between 41 and 64, and 9.26% 
aged more than 65. Among these smokers, 44.85% of them were white, 9.33% were 
black, and 45.83% were races including Hispanic and Asian. For the smokers who 
were prescribed NRT, 32.51% of them were aged between 18 and 40, 58.69% aged 
between 41 and 64, and 8.80% aged more than 65. They were mostly comprised of 
white (47.16%), followed by races (39.37%) including Hispanic and Asian, and black 
(13.47%). ConClusions: Findings of this real world study indicate that in 2011, 
varenicline was the most commonly prescribed smoking cessation medication 
followed by NRT then bupropion.
reducing LOS, episode cost, and readmission risk in hospitalized Medicare patients 
with COPD. As such, ONS may offer an opportunity to reduce costs to Medicare 
while improving quality of outcomes.
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objeCtives: Asthma is the leading cause of activity limitation and has serious 
economic consequences on the United States health care system. The nation spends 
an estimated $56 billion in health care costs annually. Various factors are associ-
ated with high health care costs. Underuse of inhaled corticosteroids, a first-line 
therapy for asthma, may be one of the drivers to high health care costs which may 
differ according to race and ethnicity. The objective of this study is to determine 
use of inhaled corticosteroids among asthma patients, the factors associated with 
use and the economic implications of underuse of medications. Methods: A ret-
rospective study was done using 2010 and 2011 Medical Expenditure Panel Survey 
(MEPS) data to identify patients with asthma who were using inhaled corticoster-
oids expressed as days of supply of medication that cover their dosage regimen. 
Socio-demographic characteristics and total health care expenditures for these 
patients were also determined. An ordinary least square regression model was built 
to identify socio-demographic factors associated with inhaled corticosteroid use and 
health care expenditures. Results: There were 151 asthma patients identified that 
reported inhaled corticosteroids use according to availability of data on days of sup-
ply. The average days of inhaled corticosteroid use among asthma patients was 129 
days over the course of a year. Ethnicity was shown to be a significant predictor of 
inhaled corticosteroid use. Hispanics were found to have significantly lower supply 
of medication (70 days) compared to non-Hispanics. Multivariate analysis showed 
that ethnicity had no effect on total health care expenditures. ConClusions: 
Ethnic disparities were found in the use of inhaled corticosteroids among asthma 
patients. However, no difference in health care expenditures shows that access is 
not an issue for ethnic groups. Future research should investigate reasons for dis-
parities in inhaled corticosteroid use among asthma patients. The main limitation 
of this study was that it was observational in nature.
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objeCtives: Increased asthma severity is associated with worsening clinical out-
comes, but little is known about economic outcomes for very severe patients. The 
objective of this study was to assess the economic and health care utilization burden 
in the year before and after treatment escalation to GINA steps 4/5. Methods: 
Using 2003-2011 Marketscan data, three asthma treatment cohorts (age 12-75) were 
identified: omalizumab, high intensity corticosteroids (HICS; ≥ 1000 µg/day inhaled 
fluticasone equivalent or oral prednisone), and high-dose inhaled corticosteroids 
(HDICS; ≥ 500 to < 1000 µg/day fluticasone equivalent). Inclusion required “stable 
therapy”, defined as three months of therapy within the first three months after 
the index (date of first prescription), and continuous eligibility. Negative binomial, 
Tobit, OLS and Logistic regressions were used depending on the outcome variable, 
controlling for sociodemographics and chronic comorbidity. Results: Of 19,227 
patients, 856 initiated omalizumab, 6,926 initiated HICS, and 11,445 initiated HDICS. 
Patients had a heavy asthma polypharmacy burden which increased with increasing 
severity. Outpatient visits, prescription drug use, home health care and specialty 
visits increased from baseline to follow-up for all treatment cohorts; however, inpa-
tient visits and ER visits declined. Annual health care expenditures increased for all 
cohorts, markedly for omalizumab (median $9,600 to $29,800). Annual out-of-pocket 
expenses (copayments, coinsurance and deductibles) increased and were substan-
tial for all three cohorts (follow-up year: Omalizumab $2,391; HICS $1,827; HDICS 
$1,457). ConClusions: Patients utilized less outpatient care and required more 
emergency and inpatient care in the year prior to treatment escalation. Patients at 
the upper end of the asthma treatment continuum experienced a heavy polyphar-
macy burden and high out-of-pocket costs after treatment escalation to omalizumab 
or medium-high dose corticosteroids, suggesting potential room for improvement 
in treatment paradigms.
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objeCtives: This study assessed the utilization and treatment patterns of smok-
ing cessation products in the Mississippi Medicaid Fee-For-Service (FFS) population 
